WO2016193779A1 - Oral pharmaceutical composition of isotretinoin - Google Patents

Oral pharmaceutical composition of isotretinoin Download PDF

Info

Publication number
WO2016193779A1
WO2016193779A1 PCT/IB2015/054090 IB2015054090W WO2016193779A1 WO 2016193779 A1 WO2016193779 A1 WO 2016193779A1 IB 2015054090 W IB2015054090 W IB 2015054090W WO 2016193779 A1 WO2016193779 A1 WO 2016193779A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
oral pharmaceutical
isotretinoin
cellulose
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/054090
Other languages
French (fr)
Inventor
Pankaj Prabhakar AMRUTKAR
Sumit Madan
Ravi Kochhar
Subodh Deshmukh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Priority to EP15894042.9A priority Critical patent/EP3302438A4/en
Priority to MX2017015322A priority patent/MX2017015322A/en
Priority to BR112017025739A priority patent/BR112017025739A2/en
Priority to CA2987517A priority patent/CA2987517A1/en
Priority to JP2017561880A priority patent/JP2018516262A/en
Priority to AU2015397336A priority patent/AU2015397336A1/en
Priority to RU2017144222A priority patent/RU2017144222A/en
Priority to PCT/IB2015/054090 priority patent/WO2016193779A1/en
Priority to US14/958,532 priority patent/US20160346241A1/en
Publication of WO2016193779A1 publication Critical patent/WO2016193779A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/006—Pressing and sintering powders, granules or fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Definitions

  • the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix.
  • the present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
  • Isotretinoin is a retinoid (also known as ⁇ 3-cis retinoic acid). Owing to its low water solubility, the oral bioavailability of isotretinoin is low.
  • PCT Publication No. WO 00/25772 discloses that the presently marketed formulation of isotretinoin, i.e. , Accutane®, contains isotretinoin at a mean particle size of about 100 ⁇ resulting in only 20% oral bioavailability. Therefore, this application discloses a formulation of isotretinoin having a reduced particle size, thereby enhancing the oral bioavailability.
  • Absorica® These patents disclose capsules comprising a semi-solid suspension of isotretinoin containing at least two lipidic excipients, one having an HLB value equal to or greater than 10 and the other being an oily vehicle. These patents are based on the use of the "Lidose technology" to provide a formulation of isotretinoin with enhanced bioavailability.
  • the oral bioavailability of a drug is affected by various factors which include aqueous solubility, first pass effect, or food-effect. Out of these, the solubility of a drug in water is one of the major factors influencing the bioavailability of that drug.
  • the bioavailability of a poorly soluble drug can be enhanced by various methods, which include particle size reduction, formation of salts or esters, complexation, or formation of solid dispersions. Isotretinoin is poorly soluble in water. Therefore, there is a need to develop a composition of isotretinoin having enhanced bioavailability.
  • the present inventors have developed an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix.
  • the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix.
  • the present invention further provides a process for preparing the oral pharmaceutical composition of the present invention. It also provides a method of treating acne by administering the oral pharmaceutical composition of the present invention.
  • the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix.
  • the pharmaceutically acceptable matrix is a polymeric matrix, a non-polymeric matrix, or a combination thereof.
  • the polymeric matrix includes, but is not limited to, hydroxypropylmethyl cellulose; hydroxypropyl cellulose; hydroxyethyl cellulose; hydroxymethyl cellulose; carboxymethyl cellulose; sodiumcarboxymethyl cellulose; carboxymethylcellulose calcium; polyvinyl pyrrolidone; polyethylene oxide; polyvinyl alcohol; methyl cellulose; ethyl cellulose; propyl cellulose; ethylmethyl cellulose; isopropyl cellulose; ethylpropyl cellulose; butyl cellulose; benzyl cellulose; cellulose esters such as cellulose acetate, cellulose butyrate, cellulose propionate, cellulose butyrate, and cellulose acetate propionate; cellulose cyanoalkyl ethers such as cyanoethyl cellulose, cyanomethyl cellulose, cyanoethylmethyl cellulose, and cyanopropyl cellulose; methacrylic acid-acrylic acid copolymers (e.g.
  • the non-polymeric matrix includes, but is not limited to, sugar and sugar alcohols for example sucrose, lactose, fructose, maltose, raffinose, sorbitol, lactitol, mannitol, maltitol, erythritol, threitol, adonitol, arabitol, xylitol, dulcitol, inositol, trehalose, isomalt, inulin, and maltodextrin; cyclodextrin, for example ⁇ -cyclodextrin and hydroxypropyl- ⁇ - cyclodextrin; polyethylene glycol; polyethylene glycol esters; medium chain triglycerides; fatty acids; fatty alcohols; waxes; fatty acid esters; polyoxyethylene sorbitan fatty acid esters; urea; and mixtures thereof.
  • sugar and sugar alcohols for example sucrose, lactose,
  • the pharmaceutically acceptable matrix is present in an amount of about 1% w/w to about 90% w/w by total weight of the composition; preferably in an amount of about 50% w/w to 85% w/w by total weight of the composition.
  • said composition comprises isotretinoin in an amount of about 1 mg to 100 mg, 5 mg to 50 mg, 10 mg to 40 mg, 9 mg to 36 mg, or 8 mg to 32 mg.
  • said composition comprises isotretinoin in an amount of about 40 mg.
  • said composition comprises isotretinoin in an amount of about 32 mg.
  • said composition comprises isotretinoin in an amount of about 16 mg.
  • said pharmaceutical composition is in the form of a solid dosage form comprising a solid dispersion of isotretinoin and a pharmaceutically acceptable matrix.
  • said pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, for example, binders, disintegrants, fillers, lubricants, glidants, surfactants, stabilizing agents, colors, flavors, preservatives, and combinations thereof.
  • pharmaceutically acceptable excipients for example, binders, disintegrants, fillers, lubricants, glidants, surfactants, stabilizing agents, colors, flavors, preservatives, and combinations thereof.
  • said oral pharmaceutical composition is stable when stored at 40°C and 75% relative humidity or at 25 °C and 60% relative humidity for a period of at least three months or to the extent necessary for the use of the composition.
  • a process for preparing said solid dispersion wherein the process is a solvent evaporation method, melting method, kneading method, co-grinding method, co-precipitation method, freeze-drying, coating, or adsorbing the drug onto carrier particles.
  • said process comprises:
  • said process comprises:
  • step b) coating or adsorbing the solution of step a) onto a pharmaceutically acceptable matrix to form solid particles or granules;
  • step b) filing the solid particles or granules of step b) into capsules or compressing into tablets with one or more pharmaceutically acceptable excipients.
  • the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition, when administered orally, provides equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica ® capsules, wherein said dose is at least 10% lower.
  • the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition, when administered orally, provides equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica ® capsules, wherein said dose is at least 20% lower.
  • the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability wherein said composition exhibits reduced food effect as indicated by comparable Cmax and AUC in fasting and fed states.
  • the present invention provides a method of treating acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging by administering to the individual in need thereof the oral pharmaceutical composition of the present invention.
  • the present invention provides a method of treating acne by administering to the individual in need thereof the oral pharmaceutical composition of the present invention.
  • isotretinoin refers to isotretinoin in its crystalline or amorphous form, its esters, salts, or derivatives thereof.
  • solid dispersion refers to a solidified form of a drug obtained by dispersing or dissolving the drug in a matrix.
  • the drug is present in a molecular state, colloidal state, metastable state, or an amorphous state.
  • Various processes for preparing solid dispersions include solvent evaporation method, melting method, kneading method, co-grinding method, co-precipitation method, freeze-drying, coating, or adsorbing the drug onto carrier particles.
  • solvent refers to any solvent or solvent mixture, aqueous and non-aqueous solvents, protic or aprotic solvents; for example, water, alcohols, esters, halogenated hydrocarbons, ketones, ethers, and mixtures thereof.
  • alcohols include, primary, secondary and tertiary alcohols, for example methanol, ethanol, n- propanol, isopropanol, and butanol.
  • the esters may include one or more of ethyl acetate, n-propyl acetate, isopropyl acetate, and n-butyl acetate.
  • halogenated hydrocarbons include dichloromethane, chloroform, and 1,2-dichloroethane.
  • ketones include acetone, methyl ethyl ketone, and the like.
  • ethers include diethyl ether and tetrahydrofuran.
  • the bioequivalence is established by comparing pharmacokinetic parameters for example, AUC and C max , of the pharmaceutical composition of the present invention with Absorica ® capsules in healthy human subjects in fed as well as fasting conditions.
  • AUC refers to the area under the time/plasma concentration curve after administration of the pharmaceutical composition
  • AUCo-Minity denotes the area under the plasma concentration versus time curve from time 0 to infinity
  • AUCo-t denotes the area under the plasma concentration versus time curve from time 0 to time t.
  • C max refers to the maximum concentration of isotretinoin in the blood following administration of the pharmaceutical composition.
  • tma X refers to the time in hours when Cma X is achieved following administration of the pharmaceutical composition.
  • food effect refers to food-drug interactions which either decrease or increase the extent of drug absorption. It refers to a relative difference in AUC, Cmax, and/or tmax of a drug, when said drug or a formulation thereof is administered orally to a human, concomitantly with food or in a fed state as compared to when administered in a fasted state or without food.
  • the one or more additional pharmaceutically acceptable excipients are selected from binders, disintegrants, fillers, lubricants, glidants, surfactants, stabilizing agents, antioxidants, alkaline stabilizers, colors, flavors, preservatives, and combinations thereof.
  • binders include, but are not limited to, methyl cellulose,
  • hydroxypropyl cellulose hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, poloxamer, gelatin, ethyl cellulose, polyvinyl alcohol, pullunan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, gum arabic, and mixtures thereof.
  • disintegrants include, but are not limited to, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodiumcarboxymethyl cellulose, calcium carboxymethyl cellulose, alginic acid, alginates, pregelatinized starch, starch and its derivatives, low-substituted hydroxypropyl cellulose, and mixtures thereof.
  • fillers include, but are not limited to, starch, lactose, sucrose, glucose, sorbitol, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, dextrates, dextrins, dextrose, fructose, lactitol, mannitol, sorbitol, pregelatinized starch, and mixtures thereof.
  • lubricants and glidants include, but are not limited to, colloidal anhydrous silica, magnesium stearate, calcium stearate, stearic acid, talc, hydrogenated castor oil, sucrose esters of fatty acid, and mixtures thereof.
  • antioxidants include, but are not limited to, butylated hydroxyl anisole, butylated hydroxyl toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof.
  • alkaline stabilizers include, but are not limited to, sodium hydroxide, potassium hydroxide, sodium carbonate or bicarbonate, potassium carbonate or bicarbonate, lithium hydroxide, triethylamine, meglumine, methylamine, and mixtures thereof.
  • suitable preservatives include, but are not limited to, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, benzoic acid, sodium benzoate, benzyl alcohol, sorbic acid, potassium sorbate, and mixtures thereof.
  • stable refers to chemical stability, wherein not more than 1.5% w/w of total related substances are formed on storage at accelerated conditions of stability at 40°C and 75% relative humidity or at 25 °C and 60% relative humidity for a period of at least three months or to the extent necessary for use of the composition.
  • step 3 Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation. 4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form
  • Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose of step 3 to form
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose of step 3 to form
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose of step 3 to form
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • Hydroxypropylmethyl cellulose E3 LV and polaxomer 188 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Polyethylene glycol 6000 and Kolliphor ® RH 40 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
  • Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
  • Stearic acid and Kolliphor ® RH 40 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 70.37:29.63) under stirring to form a clear solution.
  • Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose of step 3 to form
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Gelucire ® 43/01 and Kolliphor ® RH 40 were dissolved in a mixture of
  • Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation. 4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form granules.
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose of step 3 to form
  • step 4 The granules of step 4 were dried and filled into capsules.
  • Kolliphor ® RH 40 was dissolved in a mixture of dichloromethane and ethanol (in a ratio of 76:24) under stirring to form a clear solution.
  • Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
  • step 2 The solution of step 2 was sprayed over the loaded lactose of step 3 to form
  • step 4 The granules of step 4 were dried and filled into capsules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.

Description

ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN
Field of the Invention
The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
Background of the Invention
Isotretinoin is a retinoid (also known as \3-cis retinoic acid). Owing to its low water solubility, the oral bioavailability of isotretinoin is low. PCT Publication No. WO 00/25772 discloses that the presently marketed formulation of isotretinoin, i.e. , Accutane®, contains isotretinoin at a mean particle size of about 100 μιη resulting in only 20% oral bioavailability. Therefore, this application discloses a formulation of isotretinoin having a reduced particle size, thereby enhancing the oral bioavailability.
U.S. Patent Nos. 7,435,427 and 8,367, 102 cover the marketed formulation of
Absorica®. These patents disclose capsules comprising a semi-solid suspension of isotretinoin containing at least two lipidic excipients, one having an HLB value equal to or greater than 10 and the other being an oily vehicle. These patents are based on the use of the "Lidose technology" to provide a formulation of isotretinoin with enhanced bioavailability.
The oral bioavailability of a drug is affected by various factors which include aqueous solubility, first pass effect, or food-effect. Out of these, the solubility of a drug in water is one of the major factors influencing the bioavailability of that drug. The bioavailability of a poorly soluble drug can be enhanced by various methods, which include particle size reduction, formation of salts or esters, complexation, or formation of solid dispersions. Isotretinoin is poorly soluble in water. Therefore, there is a need to develop a composition of isotretinoin having enhanced bioavailability. The present inventors have developed an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix. Summary of the Invention
The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix. The present invention further provides a process for preparing the oral pharmaceutical composition of the present invention. It also provides a method of treating acne by administering the oral pharmaceutical composition of the present invention.
Detailed Description of the Invention
In one aspect, the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix.
In one embodiment of the above aspect, the pharmaceutically acceptable matrix is a polymeric matrix, a non-polymeric matrix, or a combination thereof.
The polymeric matrix includes, but is not limited to, hydroxypropylmethyl cellulose; hydroxypropyl cellulose; hydroxyethyl cellulose; hydroxymethyl cellulose; carboxymethyl cellulose; sodiumcarboxymethyl cellulose; carboxymethylcellulose calcium; polyvinyl pyrrolidone; polyethylene oxide; polyvinyl alcohol; methyl cellulose; ethyl cellulose; propyl cellulose; ethylmethyl cellulose; isopropyl cellulose; ethylpropyl cellulose; butyl cellulose; benzyl cellulose; cellulose esters such as cellulose acetate, cellulose butyrate, cellulose propionate, cellulose butyrate, and cellulose acetate propionate; cellulose cyanoalkyl ethers such as cyanoethyl cellulose, cyanomethyl cellulose, cyanoethylmethyl cellulose, and cyanopropyl cellulose; methacrylic acid-acrylic acid copolymers (e.g., Eudragit® RS, Eudragit® RL, Eudragit® NE, Eudragit® RS PO, and Eudragit® RL PO); methacrylic acid copolymers; hydroxypropyl methylcellulose phthalate; hydroxypropyl methylcellulose acetate succinate; cellulose acetate phthalate; and mixtures thereof.
The non-polymeric matrix includes, but is not limited to, sugar and sugar alcohols for example sucrose, lactose, fructose, maltose, raffinose, sorbitol, lactitol, mannitol, maltitol, erythritol, threitol, adonitol, arabitol, xylitol, dulcitol, inositol, trehalose, isomalt, inulin, and maltodextrin; cyclodextrin, for example β-cyclodextrin and hydroxypropyl-β- cyclodextrin; polyethylene glycol; polyethylene glycol esters; medium chain triglycerides; fatty acids; fatty alcohols; waxes; fatty acid esters; polyoxyethylene sorbitan fatty acid esters; urea; and mixtures thereof.
In another embodiment of the above aspect, the pharmaceutically acceptable matrix is present in an amount of about 1% w/w to about 90% w/w by total weight of the composition; preferably in an amount of about 50% w/w to 85% w/w by total weight of the composition.
In another embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 1 mg to 100 mg, 5 mg to 50 mg, 10 mg to 40 mg, 9 mg to 36 mg, or 8 mg to 32 mg.
In another embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 40 mg.
In another embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 32 mg.
In another embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 16 mg.
In another embodiment of the above aspect, said pharmaceutical composition is in the form of a solid dosage form comprising a solid dispersion of isotretinoin and a pharmaceutically acceptable matrix.
In another embodiment of the above aspect, said pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, for example, binders, disintegrants, fillers, lubricants, glidants, surfactants, stabilizing agents, colors, flavors, preservatives, and combinations thereof.
In yet another embodiment, said oral pharmaceutical composition is stable when stored at 40°C and 75% relative humidity or at 25 °C and 60% relative humidity for a period of at least three months or to the extent necessary for the use of the composition.
In another aspect of the present invention, there is provided a process for preparing said solid dispersion, wherein the process is a solvent evaporation method, melting method, kneading method, co-grinding method, co-precipitation method, freeze-drying, coating, or adsorbing the drug onto carrier particles. In one embodiment of the above aspect, said process comprises:
a) dissolving isotretinoin and a pharmaceutically acceptable matrix in a solvent; and
b) evaporating the solvent to form a solid dispersion of isotretinoin.
In another embodiment of the above aspect, said process comprises:
a) dissolving isotretinoin and one or more excipients in a solvent;
b) coating or adsorbing the solution of step a) onto a pharmaceutically acceptable matrix to form solid particles or granules; and
c) filing the solid particles or granules of step b) into capsules or compressing into tablets with one or more pharmaceutically acceptable excipients.
In another aspect, the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition, when administered orally, provides equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica® capsules, wherein said dose is at least 10% lower.
In another aspect, the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition, when administered orally, provides equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica® capsules, wherein said dose is at least 20% lower.
In another aspect, the present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability wherein said composition exhibits reduced food effect as indicated by comparable Cmax and AUC in fasting and fed states.
In still another aspect, the present invention provides a method of treating acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging by administering to the individual in need thereof the oral pharmaceutical composition of the present invention. In one embodiment of the above aspect, the present invention provides a method of treating acne by administering to the individual in need thereof the oral pharmaceutical composition of the present invention.
The term "isotretinoin" refers to isotretinoin in its crystalline or amorphous form, its esters, salts, or derivatives thereof.
The term "solid dispersion" refers to a solidified form of a drug obtained by dispersing or dissolving the drug in a matrix. In the solid dispersion the drug is present in a molecular state, colloidal state, metastable state, or an amorphous state.
Various processes for preparing solid dispersions include solvent evaporation method, melting method, kneading method, co-grinding method, co-precipitation method, freeze-drying, coating, or adsorbing the drug onto carrier particles.
The term "solvent" as used herein refers to any solvent or solvent mixture, aqueous and non-aqueous solvents, protic or aprotic solvents; for example, water, alcohols, esters, halogenated hydrocarbons, ketones, ethers, and mixtures thereof. Examples of alcohols include, primary, secondary and tertiary alcohols, for example methanol, ethanol, n- propanol, isopropanol, and butanol. The esters may include one or more of ethyl acetate, n-propyl acetate, isopropyl acetate, and n-butyl acetate. Examples of halogenated hydrocarbons include dichloromethane, chloroform, and 1,2-dichloroethane. Examples of ketones include acetone, methyl ethyl ketone, and the like. Examples of ethers include diethyl ether and tetrahydrofuran.
The bioequivalence is established by comparing pharmacokinetic parameters for example, AUC and Cmax, of the pharmaceutical composition of the present invention with Absorica® capsules in healthy human subjects in fed as well as fasting conditions.
The term "AUC" refers to the area under the time/plasma concentration curve after administration of the pharmaceutical composition; AUCo-Minity denotes the area under the plasma concentration versus time curve from time 0 to infinity; AUCo-t denotes the area under the plasma concentration versus time curve from time 0 to time t.
The term "Cmax" refers to the maximum concentration of isotretinoin in the blood following administration of the pharmaceutical composition.
The term "tmaX" refers to the time in hours when CmaX is achieved following administration of the pharmaceutical composition. The term "food effect" as used herein refers to food-drug interactions which either decrease or increase the extent of drug absorption. It refers to a relative difference in AUC, Cmax, and/or tmax of a drug, when said drug or a formulation thereof is administered orally to a human, concomitantly with food or in a fed state as compared to when administered in a fasted state or without food.
The one or more additional pharmaceutically acceptable excipients are selected from binders, disintegrants, fillers, lubricants, glidants, surfactants, stabilizing agents, antioxidants, alkaline stabilizers, colors, flavors, preservatives, and combinations thereof.
Examples of binders include, but are not limited to, methyl cellulose,
hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, poloxamer, gelatin, ethyl cellulose, polyvinyl alcohol, pullunan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, gum arabic, and mixtures thereof.
Examples of disintegrants include, but are not limited to, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodiumcarboxymethyl cellulose, calcium carboxymethyl cellulose, alginic acid, alginates, pregelatinized starch, starch and its derivatives, low-substituted hydroxypropyl cellulose, and mixtures thereof.
Examples of fillers include, but are not limited to, starch, lactose, sucrose, glucose, sorbitol, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, dextrates, dextrins, dextrose, fructose, lactitol, mannitol, sorbitol, pregelatinized starch, and mixtures thereof.
Examples of lubricants and glidants include, but are not limited to, colloidal anhydrous silica, magnesium stearate, calcium stearate, stearic acid, talc, hydrogenated castor oil, sucrose esters of fatty acid, and mixtures thereof.
Examples of antioxidants include, but are not limited to, butylated hydroxyl anisole, butylated hydroxyl toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof.
Examples of alkaline stabilizers include, but are not limited to, sodium hydroxide, potassium hydroxide, sodium carbonate or bicarbonate, potassium carbonate or bicarbonate, lithium hydroxide, triethylamine, meglumine, methylamine, and mixtures thereof. Examples of suitable preservatives include, but are not limited to, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, benzoic acid, sodium benzoate, benzyl alcohol, sorbic acid, potassium sorbate, and mixtures thereof.
The term "stable" as used herein, refers to chemical stability, wherein not more than 1.5% w/w of total related substances are formed on storage at accelerated conditions of stability at 40°C and 75% relative humidity or at 25 °C and 60% relative humidity for a period of at least three months or to the extent necessary for use of the composition.
The invention may be further illustrated by the following examples, which are for illustrative purposes only and should not be construed as limiting the scope of the invention in anyway.
EXAMPLES
Example 1
Figure imgf000008_0001
Procedure:
1. Povidone K30 and Kolliphor® RH 40 were dissolved in a mixture of
dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation. 4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form
granules.
5. The granules of step 4 were dried and filled into capsules. Example 2
Figure imgf000009_0001
Procedure:
1. Povidone K30 and Gelucire® 50/13 were dissolved in a mixture of
dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form
granules.
5. The granules of step 4 were dried and filled into capsules.
Example 3
Figure imgf000009_0002
Procedure:
1. Povidone K30, Kolliphor® RH 40 and Gelucire® 50/13 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 68.42:31.58) under stirring to form a clear solution. 2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form
granules.
5. The granules of step 4 were dried and filled into capsules.
Example 4
Figure imgf000010_0001
Procedure:
1. Povidone K30, Kolliphor® RH 40 and Gelucire® 50/13 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 68.42:31.58) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form
granules.
5. The granules of step 4 were dried and filled into capsules. Example 5
Figure imgf000011_0001
Procedure:
1. Povidone K30 and polaxomer 188 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
5. The granules of step 4 were dried and filled into capsules.
Example 6
Figure imgf000011_0002
Procedure:
1. Povidone K30 and Gelucire® 50/13 were dissolved in a mixture of
dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
The granules of step 4 were dried and filled into capsules.
Example 7
Figure imgf000012_0001
Procedure:
1. Povidone K30 and Kolliphor® RH 40 were dissolved in a mixture of
dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
5. The granules of step 4 were dried and filled into capsules. Example 8
Figure imgf000013_0001
Procedure:
1. Hydroxypropylmethyl cellulose E3 LV and polaxomer 188 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
5. The granules of step 4 were dried and filled into capsules.
Example 9
Figure imgf000013_0002
Procedure:
1. Hydroxypropylmethyl cellulose E15 LV and Gelucire® 50/13 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
The granules of step 4 were dried and filled into capsules.
Example 10
Figure imgf000014_0001
Procedure:
1. Polyethylene glycol 6000 and poloxamer 188 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
5. The granules of step 4 were dried and filled into capsules. Example 11
Figure imgf000015_0001
Procedure:
1. Polyethylene glycol 6000 and docusate sodium were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
5. The granules of step 4 were dried and filled into capsules.
Example 12
Figure imgf000015_0002
Procedure:
1. Polyethylene glycol 6000 and Gelucire® 50/13 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
The granules of step 4 were dried and filled into capsules.
Example 13
Figure imgf000016_0001
Procedure:
1. Polyethylene glycol 6000 and Kolliphor® RH 40 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous and croscarmellose sodium were loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose and croscarmellose sodium of step 3 to form granules.
5. The granules of step 4 were dried and filled into capsules. Example 14
Figure imgf000017_0001
Procedure:
1. Stearic acid and Kolliphor® RH 40 were dissolved in a mixture of dichloromethane and ethanol (in a ratio of 70.37:29.63) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form
granules.
5. The granules of step 4 were dried and filled into capsules.
Example 15
Figure imgf000017_0002
Procedure:
1. Gelucire® 43/01 and Kolliphor® RH 40 were dissolved in a mixture of
dichloromethane and ethanol (in a ratio of 81.48: 18.52) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation. 4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form granules.
5. The granules of step 4 were dried and filled into capsules.
Example 16
Figure imgf000018_0001
Procedure:
1. Compritol® 888 and Kolliphor® RH 40 were dissolved in a mixture of
dichloromethane and ethanol (in a ratio of 66.67:33.33) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form
granules.
5. The granules of step 4 were dried and filled into capsules.
Example 17
Ingredients Quantity (% w/w)
Isotretinoin 11.73
Lactose anhydrous 70.38
Butylated hydroxy anisole 0.29
Polyoxyl 40 hydrogenated castor oil
17.60
(Kolliphor® RH 40) Procedure:
1. Kolliphor® RH 40 was dissolved in a mixture of dichloromethane and ethanol (in a ratio of 76:24) under stirring to form a clear solution.
2. Butylated hydroxy anisole and isotretinoin were dissolved in the solution of step 1 under stirring to form a clear solution.
3. Lactose anhydrous was loaded into a fluidized bed processor bowl for granulation.
4. The solution of step 2 was sprayed over the loaded lactose of step 3 to form
granules.
5. The granules of step 4 were dried and filled into capsules.
Dissolution Studies
The release profile of the pharmaceutical compositions of Examples 1-17, is as given below:
Figure imgf000019_0002
Figure imgf000019_0003
Figure imgf000019_0004
Figure imgf000019_0001

Claims

We claim:
1. An oral pharmaceutical composition of isotretinoin having enhanced
bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix.
2. The oral pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable matrix is a polymeric matrix, a non-polymeric matrix, or a combination thereof.
3. The oral pharmaceutical composition according to claim 2, wherein the polymeric matrix is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium, polyvinylpyrrolidone, polyethylene oxide, polyvinyl alcohol, methyl cellulose, ethyl cellulose, propyl cellulose, ethylmethyl cellulose, isopropyl cellulose, ethylpropyl cellulose, butyl cellulose, benzyl cellulose, cellulose esters, cellulose cyanoalkyl ethers, methacrylic acid-acrylic acid copolymers, methacrylic acid copolymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, and mixtures thereof.
4. The oral pharmaceutical composition according to claim 2, wherein the non- polymeric matrix is selected from the group consisting of sugars, sugar alcohols, cyclodextrin, polyethylene glycol, polyethylene glycol esters, medium chain triglycerides, fatty acids, fatty alcohols, waxes, fatty acid esters, polyoxyethylene sorbitan fatty acid esters, urea, and mixtures thereof.
5. The oral pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable matrix is present in an amount of about 1% w/w to about 90% w/w by total weight of the composition.
6. The oral pharmaceutical composition according to claim 5, wherein the pharmaceutically acceptable matrix is present in an amount of about 50% w/w to about 85% w/w by total weight of the composition.
7. The oral pharmaceutical composition according to claim 1, wherein said composition comprises isotretinoin in an amount of about 1 mg to 100 mg, 5 mg to 50 mg, 10 mg to 40 mg, 9 mg to 36 mg, or 8 mg to 32 mg.
8. The oral pharmaceutical composition according to claim 7, wherein said composition comprises isotretinoin in an amount of about 40 mg.
9. The oral pharmaceutical composition according to claim 7, wherein said composition comprises isotretinoin in an amount of about 32 mg.
10. The oral pharmaceutical composition according to claim 7, wherein said composition comprises isotretinoin in an amount of about 16 mg.
11. The oral pharmaceutical composition according to claim 1, wherein said composition is in the form of a solid dosage form comprising a solid dispersion of isotretinoin and a pharmaceutically acceptable matrix.
12. The oral pharmaceutical composition according to claim 1, wherein said composition further comprises one or more pharmaceutically acceptable excipients selected from the group comprising binders, disintegrants, fillers, lubricants, glidants, surfactants, stabilizing agents, colors, flavors, preservatives, and combinations thereof.
13. The oral pharmaceutical composition according to claim 1, wherein said composition is stable when stored at 40°C and 75% relative humidity or at 25 °C and 60% relative humidity for a period of at least three months.
14. A process for preparing the oral pharmaceutical composition of claim 1, wherein said process is solvent evaporation method, melting method, kneading method, co- grinding method, co-precipitation method, freeze-drying, coating, or adsorbing the drug onto carrier particles.
15. The process according to claim 14, wherein said process comprises:
a) dissolving isotretinoin and a pharmaceutically acceptable matrix in a
solvent; and
b) evaporating the solvent to form a solid dispersion of isotretinoin.
16. The process according to claim 14, wherein said process comprises:
a) dissolving isotretinoin and one or more excipients in a solvent;
b) coating or adsorbing the solution of step a) onto a pharmaceutically
acceptable matrix to form solid particles or granules; and
c) filling the solid particles or granules of step b) into capsules or compressing into tablets with one or more pharmaceutically acceptable excipients.
17. The oral pharmaceutical composition according to claim 1, wherein said composition, when administered orally, provides equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica® capsules, wherein said dose is at least 10% lower.
18. The oral pharmaceutical composition according to claim 1, wherein said composition, when administered orally, provides equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica® capsules, wherein said dose is at least 20% lower.
19. The oral pharmaceutical composition according to claim 1, wherein said composition exhibits reduced food effect as indicated by comparable Cma and AUC in fasting and fed states.
20. The oral pharmaceutical composition according to claim 1, wherein said composition is used for the treatment of acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging.
21. The oral pharmaceutical composition according to claim 20, wherein said composition is used for the treatment of acne.
22. A method of treating acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging comprising administering a therapeutically effective amount of the oral pharmaceutical composition of claim 1.
23. The method according to claim 22, wherein the patient has acne.
PCT/IB2015/054090 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin Ceased WO2016193779A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP15894042.9A EP3302438A4 (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin
MX2017015322A MX2017015322A (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin.
BR112017025739A BR112017025739A2 (en) 2015-05-29 2015-05-29 isotretinoin oral pharmaceutical composition having increased bioavailability, process for preparing it and method of treatment
CA2987517A CA2987517A1 (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin
JP2017561880A JP2018516262A (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin
AU2015397336A AU2015397336A1 (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin
RU2017144222A RU2017144222A (en) 2015-05-29 2015-05-29 PHARMACEUTICAL ORAL COMPOSITION OF ISOTRETINOIN
PCT/IB2015/054090 WO2016193779A1 (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin
US14/958,532 US20160346241A1 (en) 2015-05-29 2015-12-03 Oral pharmaceutical composition of isotretinoin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/054090 WO2016193779A1 (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/958,532 Continuation US20160346241A1 (en) 2015-05-29 2015-12-03 Oral pharmaceutical composition of isotretinoin

Publications (1)

Publication Number Publication Date
WO2016193779A1 true WO2016193779A1 (en) 2016-12-08

Family

ID=57397385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/054090 Ceased WO2016193779A1 (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin

Country Status (9)

Country Link
US (1) US20160346241A1 (en)
EP (1) EP3302438A4 (en)
JP (1) JP2018516262A (en)
AU (1) AU2015397336A1 (en)
BR (1) BR112017025739A2 (en)
CA (1) CA2987517A1 (en)
MX (1) MX2017015322A (en)
RU (1) RU2017144222A (en)
WO (1) WO2016193779A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017203365A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Pharmaceutical compositions for treating acne
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
MA69876A1 (en) * 2022-07-01 2025-11-28 Acrotech Biopharma Inc. Pharmaceutical compositions containing isotretinoin, as well as their preparation methods and uses

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102657458B1 (en) 2016-11-02 2024-04-12 센트렉시온 테라퓨틱스 코포레이션 Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation Methods and compositions for treatment of pain using capsaicin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000179A1 (en) * 1998-06-27 2000-01-06 Won Jin Biopharma Co., Ltd. Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof
US20040009225A1 (en) * 2000-09-22 2004-01-15 Francis Vanderbist Pharmaceutical semi-solid composition of isotretinoin
CA2836228A1 (en) * 2012-12-13 2014-03-06 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545977A (en) * 1985-01-11 1985-10-08 G. D. Searle & Co. Compositions and methods for treating severe acne with isotretinoin
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
KR20050042013A (en) * 2001-10-30 2005-05-04 넥타르 테라퓨틱스 에이엘, 코포레이션 Water-soluble polymer conjugates of retinoic acid
SI2200588T1 (en) * 2007-09-25 2019-08-30 Solubest Ltd. Compositions comprising lipophilic active compounds and process for their preparation
JP2018520114A (en) * 2015-05-25 2018-07-26 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． Oral pharmaceutical composition of isotretinoin once daily

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000179A1 (en) * 1998-06-27 2000-01-06 Won Jin Biopharma Co., Ltd. Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof
US20040009225A1 (en) * 2000-09-22 2004-01-15 Francis Vanderbist Pharmaceutical semi-solid composition of isotretinoin
CA2836228A1 (en) * 2012-12-13 2014-03-06 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP3302438A4 *
WAGH ET AL.: "SOLID SELF-EMULSIFYING DRUG DELIVERY SYSTEM: PREPARATION TECHNIQUES AND DOSAGE FORMS.", INTERNATIONAL JOURNAL OF BIOPHARMACEUTICS, vol. 5, no. 2, 2014, pages 101 - 108, XP055332917, Retrieved from the Internet <URL:http://www.ijbonline.com/article/101-108.pdf> [retrieved on 20150831] *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017203365A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Pharmaceutical compositions for treating acne
US10517846B2 (en) 2016-05-26 2019-12-31 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for treating acne
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
MA69876A1 (en) * 2022-07-01 2025-11-28 Acrotech Biopharma Inc. Pharmaceutical compositions containing isotretinoin, as well as their preparation methods and uses

Also Published As

Publication number Publication date
RU2017144222A3 (en) 2019-07-17
MX2017015322A (en) 2018-03-28
US20160346241A1 (en) 2016-12-01
BR112017025739A2 (en) 2018-08-07
EP3302438A4 (en) 2019-01-09
JP2018516262A (en) 2018-06-21
RU2017144222A (en) 2019-07-02
EP3302438A1 (en) 2018-04-11
AU2015397336A1 (en) 2017-12-21
CA2987517A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
AU2012320563B2 (en) Pharmaceutical compositions comprising 40 - O - ( 2 - hydroxy) ethyl - rapamycin
US20100255089A1 (en) Pharmaceutical Compositions and Methods of Using Same
WO2016193779A1 (en) Oral pharmaceutical composition of isotretinoin
AU2014233799A1 (en) Pharmaceutical compositions comprising everolimus
US20220202698A1 (en) Extended release pharmaceutical compositions of riociguat
US10512619B2 (en) Solid oral formulation of fenretinide
EP3027174B1 (en) Pharmaceutical compositions of fingolimod
WO2008100106A1 (en) Controlled release preparation containing cilostazoland process for the preparation thereof
JP2019526591A (en) Pharmaceutical composition comprising rosuvastatin and ezetimibe and method for preparing the same
CA3008634A1 (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
US20190254977A1 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
WO2015181802A2 (en) Oral pharmaceutical composition of isotretinoin
US10406127B2 (en) Solid oral formulation of fenretinide
US20110217369A1 (en) Fenofibrate compositions
WO2013100878A1 (en) Pharmaceutical formulations comprising aripiprazole
WO2021186471A1 (en) Solid dosage forms for oral co-administration of polyphenols and transition metal ions
US20250352482A1 (en) Amorphous dosage form containing ebselen
US20220241230A1 (en) Diclofenac sachet composition
JP2022545822A (en) Thidamide pharmaceutical composition, its preparation method and its application
WO2023244684A1 (en) Formulations of 2-arylbenzimidazole compounds
WO2023073513A1 (en) Pharmaceutical composition containing combination of meloxicam and rizatriptan and process of preparation thereof
WO2016135740A1 (en) Process for preparing stable oral compositions of everolimus
HK40044014A (en) Solid dispersion of hydantoin derivative
HK1166005B (en) Tolvaptan solid dispersion and its preparation method
HK1166005A1 (en) Tolvaptan solid dispersion and its preparation method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15894042

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2987517

Country of ref document: CA

Ref document number: 2017561880

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/015322

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015397336

Country of ref document: AU

Date of ref document: 20150529

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017144222

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2015894042

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017025739

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017025739

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171129